June 7, 2013

From The Health Care Foundation of Greater Kansas City

Area health researchers watching patent case closely

by Mike Sherry

In its pursuit of cutting-edge treatments, the biotech industry balances a complex web of competing scientific and business interests. But officials at regional institutions, such as the University of Kansas Medical Center, could have a clearer landscape in which to operate within a month.

That's the expected timeframe for a U.S. Supreme Court decision in a case challenging patent on two genes linked to breast and ovarian cancer. Reporter Mike Sherry interviewed Polsinelli Science and Technology Chair Patrick Woolley about about the case and its impact on life sciences entrepreneurs.

To read the full article, click here

About Patrick Woolley

As practice group chair, Patrick C. Woolley has helped to grow the firm's Science and Technology practice from its inception to over 35 lawyers and scientists. In his practice, Mr. Woolley has worked in a variety of areas including patents, trademarks, copyright, licensing, litigation, trade secret litigation and business advice and guidance. His practice has included both domestic and foreign issues, with Mr. Woolley having done significant work in Australia, Canada, Europe and Japan. Mr. Woolley has worked with startup companies, federal agencies, individual inventors and university/research institutions. In particular, Mr. Woolley has managed the entire intellectual property portfolio for a Fortune 500 company, as well as for a major research institution. His duties have included patent and trademark preparation and prosecution, patentability secrets, freedom to operate opinions, licensing and asset management, product design around and development, business guidance for new products, and development of a portfolio to promote VC investment or sale of assets.